Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Trial Profile

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Angina pectoris; Atherosclerosis; Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRE-2
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2017 This trial has been completed in Sweden (end date: 3 Apr 2017).
    • 16 May 2017 This trial has been completed in Hungary (end date: 3 Apr 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top